Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drugs Boost Bayer Despite Crop, Consumer and Currency Concerns

Executive Summary

The still pending acquisition of Monsanto, crop science problems in Brazil and a weak showing from consumer health in the US cannot disguise the strong growth that Bayer's pharmaceuticals business is continuing to enjoy.

Advertisement

Related Content

2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
COMPASS Success Reinforces J&J/Bayer's Broad Labeling Strategy For Xarelto

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099216

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel